It was approved by the Food and Drug Administration (FDA) in April 2017 and used to treat patients with advanced stages of metastatic ALK-positive NSCLC who are resistant to certain other ALK inhibitors including crizotinib, ceritinib, and alectinib [9]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.